- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07937553
Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study. (ChromoKey)
An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.
Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC.
Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup.
These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
ChromoKey is a prospective, open-label, multicenter, two-cohort, non-randomized phase 2 study evaluating the efficacy and safety of first-line lenvatinib plus pembrolizumab (Cohort A) and later-line lenvatinib plus everolimus (Cohort B) in patients with metastatic chromophobe renal cell carcinoma (chRCC).
The study enrolls 40 patients across two independent cohorts, with 20 patients in each cohort. Eligible patients are adults with histologically confirmed metastatic chRCC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients from all International Metastatic RCC Database Consortium (IMDC) risk groups are eligible.
Cohort A includes patients who have received no previous systemic therapy for metastatic disease. Patients receive lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks.
Cohort B includes patients whose disease progresses following previous systemic therapy and who have not previously received lenvatinib. Patients receive lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily. Treatment continues until disease progression or unacceptable toxicity.
The primary endpoint is the objective response rate in each cohort, defined as the proportion of patients achieving a complete or partial response according to RECIST version 1.1.
Secondary endpoints include progression-free survival, overall survival, duration of response, and safety. Tumor response is evaluated using radiological assessments, and safety is assessed through monitoring of adverse events, clinical examinations, and laboratory investigations.
Each cohort is evaluated independently to characterize the activity and tolerability of the respective combination in its treatment setting. The study does not include randomization or a formal comparison between the two cohorts.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Ilya Tsimafeyeu
- Número de telefone: +74999054690
- E-mail: bucare@bucare.org
Locais de estudo
-
-
-
Chelyabinsk, Rússia
- Recrutamento
- Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
-
Contato:
- Natalia Glushankova
- Número de telefone: +74999054690
- E-mail: sten_to@mail.ru
-
Krasnoyarsk, Rússia
- Recrutamento
- V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
-
Contato:
- Ruslan Zukov
- Número de telefone: +74999054690
- E-mail: sten_to@mail.ru
-
Orenburg, Rússia
- Recrutamento
- Orenburg Regional Cancer Center
-
Contato:
- Makhabbat Murzalina
- Número de telefone: +74999054690
- E-mail: sten_to@mail.ru
-
Saint Petersburg, Rússia
- Recrutamento
- Dr. Berezin Medical Institute
-
Contato:
- Grigory Raskin
- Número de telefone: +74999054690
- E-mail: sten_to@mail.ru
-
Saint Petersburg, Rússia
- Recrutamento
- SBHI Leningrad regional clinical hospital, Saint-Petersburg
-
Contato:
- Andrei Lebedinets
- Número de telefone: +74999054690
- E-mail: sten_to@mail.ru
-
Saratov, Rússia
- Recrutamento
- Saratov Regional Cancer Center
-
Contato:
- Svetlana Averianova
- Número de telefone: +74999054690
- E-mail: sten_to@mail.ru
-
Ufa, Rússia
- Recrutamento
- Republican Clinical Oncology Dispensary
-
Contato:
- Alexander Sultanbaev
- Número de telefone: +74999054690
- E-mail: sten_to@mail.ru
-
Yekaterinburg, Rússia
- Recrutamento
- Sverdlovskiy Regional Oncological Dispensary
-
Contato:
- Marina Zafirova
- Número de telefone: +74999054690
- E-mail: sten_to@mail.ru
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histologically confirmed chromophobe renal cell carcinoma.
- Measurable disease according to RECIST version 1.1.
- ECOG performance status of 0-3.
- Cohort A: No prior systemic therapy for metastatic disease.
- Cohort B: Disease progression following prior systemic therapy and no previous exposure to lenvatinib
- Adequate bone marrow, hepatic, and renal function.
- Signed informed consent.
Exclusion Criteria:
- Uncontrolled or symptomatic central nervous system metastases or leptomeningeal disease.
- Uncontrolled hypertension despite appropriate antihypertensive treatment.
- Clinically significant uncontrolled cardiovascular disease.
- Active infection requiring systemic treatment.
- Active clinically significant bleeding or a high risk of severe hemorrhage.
- Major surgery without adequate postoperative recovery or a serious non-healing wound.
- Gastrointestinal conditions that significantly impair the absorption of oral study medications.
- Known severe hypersensitivity to any component of the assigned study treatment.
- Current pneumonitis or interstitial lung disease.
- Pregnancy or breastfeeding.
- Any medical or psychiatric condition that, in the investigator's judgment, compromises patient safety or adherence to study procedures.
- Cohort A only: Active autoimmune disease requiring systemic immunosuppressive treatment, or a requirement for chronic systemic immunosuppression, excluding physiological corticosteroid replacement.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort A: first-line lenvatinib plus pembrolizumab
lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks |
tablets solution |
|
Experimental: Cohort B: later-line lenvatinib plus everolimus
lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily |
tablets tablets |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective response rate
Prazo: 12 months
|
the proportion of patients achieving a complete or partial response according to RECIST version 1.1 |
12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
progression-free survival
Prazo: 24 months
|
the time from treatment initiation to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. |
24 months
|
|
overall survival
Prazo: 24 months
|
the time from treatment initiation to death from any cause |
24 months
|
|
duration of response
Prazo: 24 months
|
the time from the first documented complete or partial response to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first |
24 months
|
|
Grade 3 and higher treatment-emergent adverse events
Prazo: 24 months
|
the proportion of patients experiencing at least one treatment-emergent adverse event of grade 3 or higher according to NCI CTCAE version 5.0. |
24 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Neoplasias Urológicas
- Carcinoma
- Neoplasias Renais
- Carcinoma de Células Renais
- Produtos químicos orgânicos
- Macrolídeos
- Lactonas
- Sirolimus
- Everolimo
- Lenvatinib
Outros números de identificação do estudo
- ChromoKey
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Study results are disseminated through scientific publications and conference presentations in aggregate form.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .